Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

2.
3.

The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.

Zhang J, Rao E, Dioszegi M, Kondru R, DeRosier A, Chan E, Schwoerer S, Cammack N, Brandt M, Sankuratri S, Ji C.

Antimicrob Agents Chemother. 2007 Apr;51(4):1386-97. Epub 2007 Jan 22.

4.

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.

Siciliano SJ, Kuhmann SE, Weng Y, Madani N, Springer MS, Lineberger JE, Danzeisen R, Miller MD, Kavanaugh MP, DeMartino JA, Kabat D.

J Biol Chem. 1999 Jan 22;274(4):1905-13.

5.

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.

Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW.

J Biol Chem. 1999 Apr 2;274(14):9617-26.

6.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

7.
8.

Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.

Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA.

Virology. 2001 Sep 1;287(2):382-90.

9.

Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.

Adachi T, Tanaka R, Kodama A, Saito M, Takahashi Y, Ansari AA, Tanaka Y.

Retrovirology. 2011 Oct 22;8:84. doi: 10.1186/1742-4690-8-84.

11.

Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1alpha-binding activity.

Meta A, Torigoe N, Ito Y, Arakaki R, Nakashima H, Sugimura K.

Mol Immunol. 1999 Dec;36(18):1249-54.

PMID:
10684964
12.

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.

Virology. 2005 Jul 20;338(1):182-99.

13.

Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.

Misumi S, Takamune N, Ido Y, Hayashi S, Endo M, Mukai R, Tachibana K, Umeda M, Shoji S.

Biochem Biophys Res Commun. 2001 Aug 3;285(5):1309-16.

PMID:
11478800
14.

Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.

Laman JD, Schellekens MM, Abacioglu YH, Lewis GK, Tersmette M, Fouchier RA, Langedijk JP, Claassen E, Boersma WJ.

J Virol. 1992 Mar;66(3):1823-31. Erratum in: J Virol. 1992 Aug;66(8):5175.

15.

Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.

Robert-Guroff M, Louie A, Myagkikh M, Michaels F, Kieny MP, White-Scharf ME, Potts B, Grogg D, Reitz MS Jr.

J Virol. 1994 Jun;68(6):3459-66.

17.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

18.

A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression.

Misumi S, Endo M, Mukai R, Tachibana K, Umeda M, Honda T, Takamune N, Shoji S.

J Biol Chem. 2003 Aug 22;278(34):32335-43. Epub 2003 May 27.

19.

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.

20.

Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens.

Pastori C, Clivio A, Diomede L, Consonni R, De Mori GM, Longhi R, Colombo G, Lopalco L.

J Virol. 2008 Apr;82(8):4125-34. doi: 10.1128/JVI.02232-07. Epub 2008 Feb 6.

Supplemental Content

Support Center